Alexion Pharmaceuticals Inc. Release: Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the American Society of Hematology Annual Meeting

BioSpace Login

Enter your BioSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

Biotech and Pharmaceutical
News & Jobs

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

News | News By Subject | News by Disease | News By Date | Search News

Alexion Pharmaceuticals Inc. (ALXN) Release: Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the American Society of Hematology Annual Meeting
11/11/2009

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans. Physicians are also scheduled to report on their experience with eculizumab in patients with atypical Hemolytic Uremic Syndrome (aHUS) during the meeting. Abstracts summarizing these presentations were published today on the ASH web site and can be accessed using the links provided below. Soliris is a complement inhibitor approved for the treatment of PNH to reduce hemolysis. Soliris is currently under investigation for the treatment of aHUS.

Read at BioSpace.com

• BioSpace.com

• American Society of Hematology

• Alexion Pharmaceuticals Inc.

• Clinical - Research